A COMPARISON OF MADOPAR CR AND STANDARD MADOPAR IN THE TREATMENT OF NOCTURNAL AND EARLY-MORNING DISABILITY IN PARKINSONS-DISEASE

被引：0
|
作者：
不详
机构：
来源：
CLINICAL NEUROPHARMACOLOGY | 1989年 / 12卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：498 / 505
页数：8
相关论文
共 50 条
  • [31] NEW STRATEGIES IN THE TREATMENT OF EARLY PARKINSONS-DISEASE
    RINNE, UK
    ACTA NEUROLOGICA SCANDINAVICA, 1991, 84 : 95 - 98
  • [32] A CASE FOR EARLY LEVODOPA TREATMENT OF PARKINSONS-DISEASE
    CARACENI, T
    CLINICAL NEUROPHARMACOLOGY, 1994, 17 : S38 - S42
  • [33] LISURIDE IN COMPARISON TO BROMOCRIPTINE IN THE TREATMENT OF PARKINSONS-DISEASE
    LAIHINEN, A
    RINNE, UK
    SONNINEN, V
    SUCHY, I
    UPSALA JOURNAL OF MEDICAL SCIENCES, 1986, : 92 - 92
  • [34] THE INFLUENCE OF A STANDARD MEAL ON SINEMET CR ABSORPTION IN PATIENTS WITH PARKINSONS-DISEASE
    ROOS, RAC
    TIJSSEN, MAJ
    VANDERVELDE, EA
    BREIMER, DD
    CLINICAL NEUROLOGY AND NEUROSURGERY, 1993, 95 (03) : 215 - 219
  • [35] EARLY TREATMENT OF PARKINSONS-DISEASE - OPEN STUDIES ARE UNRELIABLE
    MYLLYLA, V
    HEINONEN, E
    BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6923): : 272 - 272
  • [36] LISURIDE PLUS SELEGILINE IN THE TREATMENT OF EARLY PARKINSONS-DISEASE
    NAPPI, G
    MARTIGNONI, E
    HOROWSKI, R
    PACCHETTI, C
    RAINER, E
    BRUGGI, P
    RUNGE, I
    ACTA NEUROLOGICA SCANDINAVICA, 1991, 83 (06): : 407 - 410
  • [37] NEW APPROACHES TO THE TREATMENT OF EARLY PARKINSONS-DISEASE - PREFACE
    RINNE, UK
    HEINONEN, EH
    ACTA NEUROLOGICA SCANDINAVICA, 1991, 84 : 5 - 5
  • [38] A CASE AGAINST EARLY LEVODOPA TREATMENT OF PARKINSONS-DISEASE
    QUINN, NP
    CLINICAL NEUROPHARMACOLOGY, 1994, 17 : S43 - S49
  • [39] LISURIDE, A DOPAMINE AGONIST IN THE TREATMENT OF EARLY PARKINSONS-DISEASE
    RINNE, UK
    NEUROLOGY, 1989, 39 (03) : 336 - 339
  • [40] COMPARISON OF LISURIDE AND BROMOCRIPTINE IN THE TREATMENT OF ADVANCED PARKINSONS-DISEASE
    LAIHINEN, A
    RINNE, UK
    SUCHY, I
    ACTA NEUROLOGICA SCANDINAVICA, 1992, 86 (06): : 593 - 595
12345